![Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis | Nature Communications Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-30615-x/MediaObjects/41467_2022_30615_Fig1_HTML.png)
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis | Nature Communications
A Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis - JDDonline - Journal of Drugs in Dermatology
![Sensitive determination and electrochemical evaluation of anticancer drug tofacitinib in pharmaceutical and biological samples using glassy carbon and boron-doped diamond electrodes - ScienceDirect Sensitive determination and electrochemical evaluation of anticancer drug tofacitinib in pharmaceutical and biological samples using glassy carbon and boron-doped diamond electrodes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0925963523000766-ga1.jpg)
Sensitive determination and electrochemical evaluation of anticancer drug tofacitinib in pharmaceutical and biological samples using glassy carbon and boron-doped diamond electrodes - ScienceDirect
![Structures of Tofacitinib 1, Lead Compound 2, and Novel JAK3 Inhibitors... | Download Scientific Diagram Structures of Tofacitinib 1, Lead Compound 2, and Novel JAK3 Inhibitors... | Download Scientific Diagram](https://www.researchgate.net/publication/309891032/figure/fig1/AS:613930795794444@1523383916216/Structures-of-Tofacitinib-1-Lead-Compound-2-and-Novel-JAK3-Inhibitors-3-8-See-also.png)
Structures of Tofacitinib 1, Lead Compound 2, and Novel JAK3 Inhibitors... | Download Scientific Diagram
![Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis | Business Wire Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis | Business Wire](https://mms.businesswire.com/media/20160224006053/en/511097/5/2486042_XELJANZ_XR_LOGO_cmyk_lock_up+%281%29.jpg)